Cryptocurrency & Digital Assets

TransAlta is converting a massive coal plant to natural gas, a pragmatic yet controversial move in the push for a cleaner, reliable energy future.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

A leading stainless steel giant partners with a spiritual organization to tackle addiction, signaling a strategic shift in corporate social responsibility.

Ashika Investment Managers launches a fund to capture India's next growth wave. Can its disciplined, data-driven strategy unlock value in a volatile market?

A landmark deal for two Airbus A321neos signals more than fleet expansion; it's a strategic play to turn Tashkent into the next major East-West air hub.

For patients with slow-growing lymphoma, "watch-and-wait" can be agonizing. A novel immunotherapy is showing promise in replacing anxiety with action.

A massive 320 MWh battery project in Belgium reveals how strategic investments in energy storage are becoming the ultimate luxury: grid stability and sustainability.

A top global forum warns of politicized trade and tech divides. How will this impact pharma supply chains, AI in medicine, and market access?

Netcapital's huge 1M share grant to its new CEO is a high-stakes play. We decode the strategy, the risk, and the ambitious revenue targets.

As Thailand braces for another toxic smog season, air purifier giant Levoit deploys a timely strategy to capture a market born from a public health crisis.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

A deep dive into 22 Fulton Street, where complex finance, green design, and affordable housing converge to reshape Newark's skyline and its community.

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

With its finances in distress, Netcapital bets its future on blockchain and a new CEO. Can a turnaround specialist navigate the crypto frontier?

As it readies for a SPAC merger, quantum leader Infleqtion hires a top aerospace veteran to scale its sensing unit for defense and commercial markets.

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.